formestane vs megestrol acetate | No demonstrated result suggested vaginal bleeding by 92% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
clinical benefit | 0.87 [0.48 1.58] | p=1.00 | 0 | 177 | 1 | Thuerlimann, | objective response (ORR) | 1.18 [0.81 1.73] | p=1.00 | 0 | 724 | 2 | Thuerlimann,Freue, | progression or death (progression free survival PFS) | 1.02 [0.64 1.60] | p=1.00 | 0 | -36 | 2 | Thuerlimann,Freue, | hot flushes | 1.27 [0.76 2.11] | p=1.00 | 0 | 718 | 2 | Thuerlimann,Freue, | rash | 1.31 [0.29 5.91] | p=1.00 | 0 | 547 | 1 | Freue, | vaginal bleeding | 0.08 [0.01 0.58] | p=0.04 | 0 | 547 | 1 | Freue, | thromboembolic AE | 0.13 [0.02 1.07] | p=1.00 | 0 | 171 | 1 | Thuerlimann, | arthralgia | no data | vomiting | no data | diarrhoea | no data | nausea | 0.98 [0.38 2.51] | p=1.00 | 0 | 547 | 1 | Freue, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |